Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00979849 · ClinicalTrials.gov registry record · Phase 1

AZD8683 Single Ascending Dose Study

A Phase 1 study of Healthy Volunteers, sponsored by AstraZeneca.

Completed
Registry status
Phase 1
Development phase
130
Enrollment target
1
Study location

NCT00979849 is a Phase 1 study of Healthy Volunteers that has completed, run by AstraZeneca. The registered enrollment target is 130 participants, below the 481-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00979849, a Phase 1 study of Healthy Volunteers, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 1
Development phase
130 participants
Enrollment target
1
Study location

Study Summary

The aim of the study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8683 following single ascending dose administrations in healthy male subjects.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG AZD8683

Study Locations (1)

Pennsylvania

  • Research Site - Philadelphia

Trial Details

FieldValue
Enrollment Target 130 participants
Start Date 2009-10
Est. Completion 2010-01
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

What the Registry Record Tells You About NCT00979849

The ClinicalTrials.gov registry entry for NCT00979849 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 481-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (73% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00979849 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00979849 about?

NCT00979849 is a clinical study titled "AZD8683 Single Ascending Dose Study". The aim of the study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8683 following single ascending dose administrations in healthy male subjects.

What is the current status of trial NCT00979849?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 130 participants. The study started on 2009-10. Estimated completion is 2010-01.

What conditions does trial NCT00979849 study?

This clinical trial studies the following conditions: Healthy Volunteers.

What interventions are being tested in trial NCT00979849?

The interventions under investigation include: Placebo (DRUG), AZD8683 (DRUG).

Who is sponsoring clinical trial NCT00979849?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00979849 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteers

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.